MarketInOut Stock Screener Log In | Sign Up
 

Valion Bio Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Valion Bio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1.97 mln
Float0.89 mln
Earnings Date11/13/2026

Piotroski F-Score

1 / 9
Very weak

Beneish M-Score

-3.75
Highly reliable

Relative Strength

1 / 100
Severely lagging

Debt / Equity

1.47
Elevated leverage

Pre-Tax Margin

-10,875%
Severely loss-making

ROE

-160
Deeply negative

Business Description

Valion Bio Inc. is a late-stage pharmaceutical company based in San Antonio, Texas, focused on developing treatments for radiation-related injuries and immune system disorders. Its main drug, Entolimod, is being tested for acute radiation syndrome, low white blood cell counts, and immune exhaustion, while a related compound called Entolasta targets long-term conditions linked to aging immune systems. The company also provides contract manufacturing services to other life sciences businesses. Originally founded in 2016 under the name Tivic Health Systems Inc., it adopted its current name in April 2026.

Key Fundamentals

EPS-178
ROE-160
ROIC-88.38
ROA-78.11
Interest Cover-12.33
EBITDA, mln-14.00
EV / EBITDA-1.79
EV / EBIT-1.72
Revenue, mln0.15
EV / Revenue171

Quote Details

Last 0.94
Change -0.0161 (-1.68%)
Open 0.91
Volume 40,538
Turnover 38,106
Average Volume 3,337,385

Financial Ratios

Pre-Tax Profit Margin-10,875
Leverage Ratio2.73
Current Ratio1.11
Price / Book0.11
Debt / Equity1.47
Price / Sales0.99

Financial Strength

Altman Z-Score-4.42
Piotroski F-Score 1 / 9
Beneish M-Score-3.75
Short Ratio0.03
Short % of Float9.96

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -19.66% 6 / 100   
1 Month -72.99% 1 / 100   
2 Months -89.59% 1 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog